Latest Commercial Strategy News

Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.

Metal Powder Works has converted its first copper infiltration order into a two-year agreement worth approximately US$600,000, adding contracted demand ahead of its planned capacity expansion. Supply is scheduled to begin in January 2027.

Leeuwin Metals ended FY2026 with a 342,300-ounce Marda resource, which increased to 378,600 ounces shortly after year end following further Evanston drilling. The gold explorer is now shifting towards permitting and mine planning, although it remains loss-making, has no Ore Reserves and expects to require further funding.

Adisyn Ltd reshuffles leadership with Kevin Crofton stepping up as Executive Chairman while Arye Kohavi moves to a Non-Executive Director role, signalling a strategic pivot to accelerate commercial execution in semiconductor technology.

Imricor Medical Systems has reached a crucial milestone as the FDA accepts and closes the manufacturing module of its Premarket Approval submission, advancing its MR-guided electrophysiology devices closer to US market entry.

1414 Degrees has acquired full ownership of the Aurora Energy Precinct, consolidating control to drive development of renewable energy infrastructure and a 1 GW AI data centre project.

Artrya has launched its AI-powered Salix® platform commercially in the US, securing three foundation health systems and raising $80 million to fuel growth. With FDA clearance for its Coronary Plaque module and a pivotal clinical study underway, the company is poised for scaling revenues amid a strong balance sheet.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.